# PhRMA - Pharmaceutical Research and Manufacturers of America

> La lobby piu' potente del settore farmaceutico USA, con $32M di spesa lobbying annua e un fatturato di $455M - caso emblematico di revolving door con Billy Tauzin

## Executive Summary

| Metrica | Valore |
|---------|--------|
| **Fondazione** | 1958 |
| **Sede** | Washington DC, USA |
| **Tipo** | Trade association / Lobby |
| **President & CEO** | Stephen J. Ubl (2015-) |
| **Board Chair** | Daniel O'Day (Gilead CEO) |
| **Revenue** | $455M (2017) |
| **Lobbying 2024** | $31.7M |
| **Status** | active |

---

## Glossario

| Termine | Definizione |
|---------|-------------|
| Trade association | Associazione di categoria che rappresenta interessi industriali |
| Revolving door | Passaggio di funzionari tra settore pubblico e privato |
| IRA | Inflation Reduction Act (2022) - legge USA con pricing farmaci |
| Medicare Part D | Programma Medicare per farmaci (2003) |

---

## Fondazione e Storia

| Dato | Dettaglio |
|------|-----------|
| **Fondazione** | 1958 |
| **Nome originale** | Pharmaceutical Manufacturers Association |
| **Rinomina** | 1994 (PhRMA) |
| **Contesto** | Rappresentare industria farmaceutica USA |
| **Obiettivo dichiarato** | "Represent biopharmaceutical researchers and biotechnology companies" |

### Timeline Storica

| Anno | Evento |
|------|--------|
| **1958** | Fondazione come Pharmaceutical Manufacturers Association |
| **1994** | Rinomina in PhRMA per enfatizzare R&D |
| **2003** | Medicare Modernization Act (Part D) - PhRMA lobbying chiave |
| **2005** | Billy Tauzin diventa President (revolving door) |
| **2010** | Tauzin lascia dopo accordo Obama su ACA |
| **2015** | Stephen Ubl diventa President & CEO |
| **2022** | Inflation Reduction Act - PhRMA perde battaglia su drug pricing |
| **2022-23** | Exit AbbVie, AstraZeneca, Teva (perdita $100M dues) |
| **2024** | Record lobbying: $31.7M |
| **2025** | Record pace: $227M industria H1 |

---

## Struttura e Governance

### Leadership Attuale

| Ruolo | Nome | Dal | Azienda |
|-------|------|-----|---------|
| **President & CEO** | [Stephen Ubl](../persons/stephen-ubl.md) | 2015 | PhRMA |
| **Board Chair** | [Daniel O'Day](../persons/daniel-oday.md) | 2024 | [Gilead](../pharma/gilead.md) |
| **Board Chair-elect** | [Albert Bourla](../persons/albert-bourla.md) | 2024 | [Pfizer](../pharma/pfizer.md) |
| **Treasurer** | [Paul Hudson](../persons/paul-hudson.md) | 2024 | [Sanofi](../pharma/sanofi.md) |
| **COO** | Lori M. Reilly | - | PhRMA |
| **Chief Public Affairs** | Robert Zirkelbach | - | PhRMA |

### Ex-Presidents

| Nome | Periodo | Note |
|------|---------|------|
| [Billy Tauzin](../persons/billy-tauzin.md) | 2005-2010 | Ex-Congressman, $2M+/anno salary |
| John Castellani | 2010-2015 | Ex-Business Roundtable |
| [Stephen Ubl](../persons/stephen-ubl.md) | 2015- | Ex-AdvaMed |

### Board Chairs Recenti

| Nome | Periodo | Azienda |
|------|---------|---------|
| [Albert Bourla](../persons/albert-bourla.md) | 2022-2023 | Pfizer |
| [Vas Narasimhan](../persons/vas-narasimhan.md) | 2023-2024 | Novartis |
| [Daniel O'Day](../persons/daniel-oday.md) | 2024- | Gilead |

---

## Membri

### Aziende Membro (2024)

| Azienda | CEO | Note |
|---------|-----|------|
| [Pfizer](../pharma/pfizer.md) | Albert Bourla | Chair-elect |
| [Novartis](../pharma/novartis.md) | Vas Narasimhan | Ex-Chair |
| [Gilead](../pharma/gilead.md) | Daniel O'Day | Chair |
| [Sanofi](../pharma/sanofi.md) | Paul Hudson | Treasurer |
| [Merck](../pharma/merck.md) | Robert Davis | - |
| [Johnson & Johnson](../pharma/johnson-johnson.md) | Joaquin Duato | - |
| [GSK](../pharma/gsk.md) | Emma Walmsley | - |
| [Eli Lilly](../pharma/eli-lilly.md) | David Ricks | - |
| [Bristol Myers Squibb](../pharma/bms.md) | Chris Boerner | - |
| [Amgen](../pharma/amgen.md) | Robert Bradway | - |
| [Biogen](../pharma/biogen.md) | Chris Viehbacher | - |
| [Genentech](../pharma/genentech.md) | - | Roche subsidiary |
| [Novo Nordisk](../pharma/novo-nordisk.md) | Lars Jorgensen | - |
| [Bayer](../pharma/bayer.md) | Bill Anderson | - |
| Boehringer Ingelheim | Hubertus von Baumbach | Private |

### Exit Recenti (2022-2023)

| Azienda | Exit | Motivo |
|---------|------|--------|
| AbbVie | Dic 2022 | Post-IRA |
| Teva | Feb 2023 | Cost-effectiveness |
| AstraZeneca | Mag 2023 | Post-IRA |

**Impatto**: Perdita ~$100M in membership dues annuali.

---

## Lobbying

### Spesa Annuale

| Anno | Spesa | Note |
|------|-------|------|
| **2017** | $128M | (di $455M revenue) |
| **2023** | $27M | - |
| **2024** | $31.7M | Record |
| **2025 H1** | $20.6M | On pace for new record |

### Industria Pharma Totale

| Anno | Spesa Totale |
|------|--------------|
| **2024** | $388M (record) |
| **2025 H1** | $227M (pace $450M+) |

### Focus Lobbying 2024-2025

1. **IRA Implementation** - Limitare negoziazione prezzi Medicare
2. **PBM Reform** - Spostare blame su intermediari
3. **340B** - Ridurre programma ospedali
4. **Patent Protection** - Preservare esclusivita'
5. **Weight-loss Drugs** - Espandere copertura Medicare

---

## Casi Emblematici

### 1. Billy Tauzin: Revolving Door

```
CONGRESSMAN (1980-2004)
   Chair House Energy & Commerce Committee
         |
         v
MEDICARE PART D (2003)
   Divieto negoziazione prezzi Medicare
         |
         v (2 mesi dopo)
PhRMA PRESIDENT (2005)
   Salary: $2M/anno → $11.6M (2010)
```

**Pattern**: Tauzin scrisse legge favorevole a pharma, poi assunto da pharma.

**Critica Public Citizen**: "May have been negotiating for the lobbying job while writing the Medicare legislation."

### 2. Medicare Part D (2003)

| Aspetto | Dettaglio |
|---------|-----------|
| **Legge** | Medicare Prescription Drug, Improvement, and Modernization Act |
| **Clausola chiave** | Divieto negoziazione prezzi per Medicare |
| **Beneficiario** | Industria pharma |
| **Architetto** | Billy Tauzin (poi CEO PhRMA) |
| **Durata divieto** | 2003-2022 (19 anni) |

### 3. Inflation Reduction Act (2022)

| Aspetto | Dettaglio |
|---------|-----------|
| **Legge** | IRA - Inflation Reduction Act |
| **Impatto** | Prima negoziazione prezzi Medicare |
| **Risposta PhRMA** | Causa legale (persa) |
| **Conseguenza** | Exit 3 aziende membro |

---

## Connessioni PowerLink

### Forum correlati

| Forum | Sovrapposizione |
|-------|-----------------|
| [Business Roundtable](../think-tank/business-roundtable.md) | Diversi CEO pharma membri |
| [WEF](../forum/wef.md) | CEO pharma partecipanti Davos |
| [BIO](../agency/bio.md) | Biotech lobby complementare |

### Figure chiave

| Persona | Ruolo |
|---------|-------|
| [Albert Bourla](../persons/albert-bourla.md) | Chair-elect, CEO Pfizer |
| [Vas Narasimhan](../persons/vas-narasimhan.md) | Ex-Chair, CEO Novartis |
| [Billy Tauzin](../persons/billy-tauzin.md) | Ex-President (revolving door case) |
| [Stephen Ubl](../persons/stephen-ubl.md) | President & CEO |
| [Daniel O'Day](../persons/daniel-oday.md) | Chair, CEO Gilead |

### Agenzie Regolatori

| Agenzia | Relazione |
|---------|-----------|
| [FDA](../agency/fda.md) | Target lobbying, revolving door |
| CMS | Target lobbying (Medicare pricing) |
| HHS | Target lobbying |

---

## Critiche

| Tema | Dettaglio |
|------|-----------|
| **Revolving door** | Tauzin caso emblematico: Congressman → CEO $2M |
| **Drug pricing** | Lobbying contro negoziazione prezzi 2003-2022 |
| **Political spending** | $500K-$1M ciascuno a Trump inaugural 2025 |
| **Lawsuits** | Cause contro IRA (perse) |
| **Exits** | 3 major companies left post-IRA |

---

## Pattern Identificati

### 1. Lobbying as Core Business

```
Revenue $455M
     |
     +---> 28% ($128M) → Lobbying
     |
     +---> Spesa in crescita costante
```

### 2. CEO Rotation as Chair

```
Pfizer CEO (Bourla) → Chair 2022
         |
         v
Novartis CEO (Narasimhan) → Chair 2023
         |
         v
Gilead CEO (O'Day) → Chair 2024
```

**Pattern**: CEO Big Pharma ruotano come Chair, coordinando interessi industria.

### 3. Legislative Capture

```
1. Write legislation (Medicare Part D)
2. Block price negotiation (19 years)
3. Hire architect (Tauzin)
4. Sue when overturned (IRA lawsuits)
```

---

## Fonti

### Ufficiali
- [PhRMA - About](https://phrma.org/about)
- [PhRMA - Leadership](https://phrma.org/about/leadership)
- [PhRMA - Bourla Chair](https://phrma.org/resources/dr-albert-bourla-of-pfizer-becomes-new-chair-of-phrma-board)
- [PhRMA - O'Day Chair](https://phrma.org/resources/daniel-o-day-new-chair-of-phrma-board)

### Wikipedia
- [Wikipedia - PhRMA](https://en.wikipedia.org/wiki/Pharmaceutical_Research_and_Manufacturers_of_America)
- [Wikipedia - Billy Tauzin](https://en.wikipedia.org/wiki/Billy_Tauzin)

### Lobbying Data
- [OpenSecrets - PhRMA](https://www.opensecrets.org/orgs/pharmaceutical-research-manufacturers-of-america/summary?all=2024&id=D000000504)
- [Read Sludge - Record Lobbying 2025](https://readsludge.com/2025/08/29/pharmaceutical-industry-on-pace-for-record-lobbying-spending/)
- [Modern Healthcare - Lobbying 2025](https://www.modernhealthcare.com/politics-regulation/mh-healthcare-lobbying-2025-phrma-aha/)

### Member Exits
- [STAT News - Revenue Decline](https://www.statnews.com/2024/12/23/phrma-membership-dues-revenue-decline-abbvie-astrazeneca-teva-quit/)

### Revolving Door
- [Sunlight Foundation - Tauzin Legacy](https://sunlightfoundation.com/2010/02/12/the-legacy-of-billy-tauzin-the-white-house-phrma-deal/)
- [NBC News - Tauzin aided drug firms](https://www.nbcnews.com/id/wbna11714763)
- [Bill Moyers - The Lobbyist](https://billmoyers.com/story/the-man-who-made-you-pay-more-at-the-drugstore/)

---

*Ultimo aggiornamento: Dicembre 2025*
